Differentiation Between Renal Cell Carcinoma Metastases to the Pancreas and Pancreatic Neuroendocrine Tumors in Patients with Renal Cell Carcinoma on CT or MRI

Overview

Journal Abdom Radiol (NY)

Publisher Springer

Specialties Gastroenterology
Radiology

Date 2025 Jan 8

PMID 39775027

Authors

Marie-Joy Nduwimana

Ceylan Colak

Cem Bilgin

Blake A Kassmeyer

Candice M Bolan

Christine O Menias

Sudhakar K Venkatesh

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether renal cell carcinoma metastases (RCC-Mets) to the pancreas can be differentiated from pancreatic neuroendocrine tumors (PNETs) in patients with RCC on CT or MRI at presentation.

Methods: This retrospective study included patients with biopsy-proven RCC-Mets (n = 102) or PNETs (n = 32) at diagnosis or after nephrectomy for RCC. Inter-observer agreement (Cohen kappa) was assessed in 95 patients with independent reads by two radiologists, with discrepancies resolved by consensus for final analysis. The remaining 39 cases underwent consensus reads by two different radiologists for final analysis. The CT/MRI images were reviewed for number, size, regional distribution, parenchymal location (exophytic or intrapancreatic), contrast-enhancement, and enhancement pattern of pancreatic lesions in the available phases. Statistical tests were conducted using two sample t-tests and Pearson's chi-squared test for numeric and categorical variables respectively.

Results: The study group comprised of 134 patients (90 males) with 265 lesions (229 RCC-Mets and 36 PNETs). Patients with PNETs were significantly younger (62 ± 12 years vs. 67 ± 9 years, p = 0.013). Inter-observer agreement for CT/MRI features was excellent across multiple imaging variables (k = 0.86-1.00). Most PNETs were single lesions (88 vs. 63%, p = 0.008), smaller in size (14 mm vs. 23 mm, p = 0.042), more common in the body and tail (81 vs. 57%, p = 0.01), showed homogeneous contrast enhancement (64-79% vs. 39-49%, p < 0.01-0.03), less T1-hypointense (80 vs. 99%, p = 0.002) and more DWI hyperintense (71 vs. 58%, p < 0.001) compared to RCC-Mets.

Conclusion: PNETs are typically single, occur in distal pancreas, and enhance homogeneously compared to RCC-Mets which are often multiple, occur in the proximal pancreas, and enhance heterogeneously.

References

Ballarin R, Spaggiari M, Cautero N, De Ruvo N, Montalti R, Longo C . Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol. 2011; 17(43):4747-56. PMC: 3229623. DOI: 10.3748/wjg.v17.i43.4747. View

Cheng S, Chuah K . Metastatic Renal Cell Carcinoma to the Pancreas: A Review. Arch Pathol Lab Med. 2016; 140(6):598-602. DOI: 10.5858/arpa.2015-0135-RS. View

Lyu H, Cao J, Wang H, Wang Z, Hu M, Ma L . Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. Abdom Radiol (NY). 2018; 43(10):2712-2720. DOI: 10.1007/s00261-018-1539-7. View

Brozzetti S, Sterpetti A . Unexpected Prolonged Survival After Extended and Emergent Resection of Pancreatic Metastases from Renal Cell Carcinoma. J Gastrointest Cancer. 2019; 50(4):1055-1058. DOI: 10.1007/s12029-019-00209-w. View

Lavu H, Yeo C . Metastatic renal cell carcinoma to the pancreas. Gastroenterol Hepatol (N Y). 2012; 7(10):699-700. PMC: 3265016. View

van der Pol C, Lee S, Tsai S, Larocque N, Alayed A, Williams P . Differentiation of pancreatic neuroendocrine tumors from pancreas renal cell carcinoma metastases on CT using qualitative and quantitative features. Abdom Radiol (NY). 2019; 44(3):992-999. DOI: 10.1007/s00261-018-01889-x. View

Matsubayashi H, Niwakawa M, Uesaka K, Sasaki K, Kiyozumi Y, Ishiwatari H . Renal Cell Carcinoma and a Pancreatic Neuroendocrine Tumor: A Coincidence or Instance of Von Hippel-Lindau Disease?. Intern Med. 2017; 56(17):2281-2284. PMC: 5635299. DOI: 10.2169/internalmedicine.8347-16. View

Osawa A, Sumiyama Y, Watanabe M, Tanaka H, Asai K, Enomoto T . Single case of renal cell carcinoma and endocrine pancreatic head cancer occurring with von Hippel-Lindau disease. J Hepatobiliary Pancreat Surg. 2006; 13(2):174-80. DOI: 10.1007/s00534-005-1041-9. View

Ro C, Chai W, Yu V, Yu R . Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin J Cancer. 2012; 32(6):312-24. PMC: 3845620. DOI: 10.5732/cjc.012.10295. View

10.

Kang T, Kim S, Lee J, Kim A, Jang K, Choi D . Differentiation between pancreatic metastases from renal cell carcinoma and hypervascular neuroendocrine tumour: Use of relative percentage washout value and its clinical implication. Eur J Radiol. 2015; 84(11):2089-96. DOI: 10.1016/j.ejrad.2015.08.007. View

11.

Kataoka K, Ishikawa T, Ohno E, Mizutani Y, Iida T, Ishikawa E . Differentiation between pancreatic metastases from renal cell carcinoma and pancreatic neuroendocrine neoplasm using endoscopic ultrasound. Pancreatology. 2021; 21(7):1364-1370. DOI: 10.1016/j.pan.2021.07.001. View

12.

Vaghaiwalla T, Keutgen X . Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020; 29(2):243-252. DOI: 10.1016/j.soc.2019.11.008. View

13.

Lee D, Kim M, Kim H . Diagnosis of Pancreatic Neuroendocrine Tumors. Clin Endosc. 2017; 50(6):537-545. PMC: 5719919. DOI: 10.5946/ce.2017.131. View

14.

Thadani A, Pais S, Savino J . Metastasis of renal cell carcinoma to the pancreas 13 years postnenhrectomv. Gastroenterol Hepatol (N Y). 2012; 7(10):697-9. PMC: 3265015. View

15.

Shankar P, Wasnik A, Al-Hawary M, Francis I, Kaza R . Hypervascular pancreatic "lesions": a pattern-based approach to differentiation. Abdom Radiol (NY). 2017; 43(4):1013-1028. DOI: 10.1007/s00261-017-1363-5. View

16.

Bello H, Sekhar A, Filice R, Radmard A, Davarpanah A . Pancreaticoduodenal Groove: Spectrum of Disease and Imaging Features. Radiographics. 2022; 42(4):1062-1080. DOI: 10.1148/rg.210168. View